Placebo controlled,randomised,crossover study of the efficacy of bosentan in the management of patients with Coronary Slow Flow Phenemeno

Phase 2

Recruiting

• Conditions: Coronary Slow Flow Phenomenon; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12608000236392
• Lead Sponsor: Cenral Northern Adelaide Health Service - The Queen Elizabeth Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-05-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Coronary Slow Flow Phenomenon. Angina frquency>3 episodes/week

Exclusion Criteria

Pulmonary hypertension,liver disease.Cyclosporin,glibenclamide,ketoconazole

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Angina frequency[Week 4 and week 9 assessed by angina diary recorded by patient]

Secondary Outcome Measures

Name	Time	Method
itrate consumption[Week 4 and week 9 assessed by angina diary recorded by patient];Quality of life indices measured are Seattle Angina Questionnaire ,SF 36, Quality of Life Scale[Week 4 and week 9]